NCT05040373Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Alnylam Pharmaceuticals

Start Date

8/1/2020

Completion Date

10/12/2030

Summary

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: * Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy Exclusion Criteria: * There are no exclusion criteria for participation in this program.

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Hereditary Transthyretin-mediated (hATTR) AmyloidosisPolyneuropathy

Locations

Clinical Trial Site

Iowa City, Iowa 52242

United States

Clinical Trial Site

Nantes,

France

Clinical Trial Site

Münster,

Germany

Clinical Trial Site

Pavia,

Italy

Clinical Trial Site

Groningen,

Netherlands

Clinical Trial Site

Lisbon,

Portugal

Clinical Trial Site

Madrid,

Spain